Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238

  • Authors:
    • Artur Plonowski
    • Andrew V. Schally
    • Attila Nagy
    • Baodong Sun
    • Gabor Halmos
  • View Affiliations

  • Published online on: February 1, 2002     https://doi.org/10.3892/ijo.20.2.397
  • Pages: 397-402
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We evaluated the effectiveness of targeted cytotoxic analog of somatostatin (SST) AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201) linked covalently to SST octapeptide carrier RC-121 in DU-145 human androgen-independent prostate cancers xenografted into nude mice. We also investigated the expression of mRNAs for SST receptor subtypes 2A and 5 (sst2A and sst5) in DU-145 tumors. After 8 weeks of treatment, AN-238 practically arrested the proliferation of DU-145 cancers. The tumor volume in nude mice that received 4 injections of AN-238 at the dose of 150 nmol/kg was 63.4±6.7 mm3, nearly 4 times smaller than that in controls which measured 249.1±36.3 mm3 (p<0.001). Treatment with AN-238 lowered tumor weight by 68% (p<0.01) compared with the control group and extended the tumor volume doubling time to 184.1±69.4 days, versus 32.1±6.6 days in controls (p<0.05). No toxicity-related deaths occurred during treatment with AN-238. Cytotoxic radical AN-201 administered alone or in an unconjugated mixture with carrier RC-121 inhibited the growth of DU-145 tumors only after the third and fourth injection and was toxic. The expression of mRNA for sst2A and sst5 was detected in all specimens of control DU-145 tumors and in tumors treated with AN-238. The present study demonstrates the high efficacy of SST-receptor-targeted chemotherapy in a model of human androgen-independent prostatic carcinoma.

Related Articles

Journal Cover

February 2002
Volume 20 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Plonowski A, Schally AV, Nagy A, Sun B and Halmos G: Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. Int J Oncol 20: 397-402, 2002.
APA
Plonowski, A., Schally, A.V., Nagy, A., Sun, B., & Halmos, G. (2002). Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. International Journal of Oncology, 20, 397-402. https://doi.org/10.3892/ijo.20.2.397
MLA
Plonowski, A., Schally, A. V., Nagy, A., Sun, B., Halmos, G."Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238". International Journal of Oncology 20.2 (2002): 397-402.
Chicago
Plonowski, A., Schally, A. V., Nagy, A., Sun, B., Halmos, G."Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238". International Journal of Oncology 20, no. 2 (2002): 397-402. https://doi.org/10.3892/ijo.20.2.397